Managed Account Advisors’s Arbutus Biopharma ABUS Stock Holding History

Managed Account Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$0	Sell	37 -10	-21%	-$152	﹤0.01%	3007
2015 Q1	$1K	Buy	47 +38	+422%	+$778	﹤0.01%	2922
2014 Q4	$0	Buy	+9	New	+$155	﹤0.01%	2711
2014 Q2	–	Sell	-1,607	Closed	-$35K	–	2628
2014 Q1	$35K	Buy	+1,607	New	+$28.9K	﹤0.01%	2415

Other funds holding ABUS

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Managed Account Advisors's ABUS Position: Q2 2015 in Review

Managed Account Advisors reduced its Arbutus Biopharma (ABUS) stake by 21% in Q2 2015, selling an estimated $152 and leaving 37 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

Managed Account Advisors first reported a position in ABUS in Q1 2014 and has held it in 4 quarters since. The position peaked at $35K in Q1 2014. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

Managed Account Advisors held 37 shares of Arbutus Biopharma worth $0 as of Q2 2015.
Managed Account Advisors sold 10 Arbutus Biopharma shares in Q2 2015, an estimated $152.
Arbutus Biopharma made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #3007 holding.
Managed Account Advisors first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 4 quarters since.
Managed Account Advisors's Arbutus Biopharma position peaked at $35K in Q1 2014.
63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.